Concepedia

LBO-004 Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis delta and 96 weeks of posttreatment follow-up

Heiner Wedemeyer, Soo Aleman, Antje Blank, Pietro Andreoné, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova,

Journal of Hepatology · 2025 · 10 citations · 0 references

DOI

Concepts